Extended Data Figure 8.
Chronic glucagon treatment reverses NAFLD and glucose intolerance in WT but not InsP3R-I KO mice. (a) Body weight (n=10 WT-glucagon, 11 WT+glucagon, 8 KO-glucagon, and 8 KO+glucagon). (b)-(c) Food and water intake. In panels (b)-(g), n=8 WT-glucagon, 9 WT+glucagon, 7 KO-glucagon, 8 KO+glucagon. (d) Energy expenditure. (e)-(f) Oxygen consumption and carbon dioxide production. (g) Activity. (h) Plasma NEFA. In panels (h)-(j), n=10 WT-glucagon, 11 WT+glucagon, 8 KO-glucagon, 8 KO+glucagon. (i)-(j) Glucose and insulin area under the curve during an intraperitoneal glucose tolerance test. In all panels, the mean±S.E.M. is shown. Statistical comparisons were performed using the 2-tailed unpaired Student’s t-test. If no statistical comparison is denoted, the groups were not significantly different.